Heart failure is a massive topic for the UKMLA AKT, so let's break this down into the three specific areas you asked about. It's all about identifying the severity, using the right markers for diagnosis, and following the NICE-guided management ladder.

1. NYHA Classification

The New York Heart Association (NYHA) system is used to grade the severity of functional impairment. It's a classic exam favorite!

• Class I: No limitation. Ordinary physical activity does not cause undue fatigue, dyspnoea, or palpitations.
• Class II: Slight limitation. Comfortable at rest, but ordinary physical activity results in symptoms.
• Class III: Marked limitation. Comfortable at rest, but less than ordinary activity causes symptoms.
• Class IV: Unable to carry out any physical activity without discomfort. Symptoms may be present even at rest.

2. BNP Interpretation

B-type Natriuretic Peptide (BNP) or NT-proBNP are the "gold standard" screening tools when you suspect heart failure.

• High Sensitivity: A normal NT-proBNP level makes heart failure very unlikely (high negative predictive value).
• Referral Thresholds (NICE Guidelines):
  • NT-proBNP > 2,000 pg/mL: Urgent referral for specialist assessment and echocardiogram within 2 weeks.
  • NT-proBNP 400–2,000 pg/mL: Routine referral for specialist assessment and echocardiogram within 6 weeks.
  • NT-proBNP < 400 pg/mL: Heart failure is unlikely; look for other causes.

Note: BNP can be falsely elevated by age, renal impairment, or atrial fibrillation, and falsely lowered by obesity or certain medications (like ACEi/Beta-blockers).

3. Stepwise Treatment (HFrEF)

For Heart Failure with reduced Ejection Fraction (HFrEF), we follow a specific sequence to improve survival and reduce hospitalisations.

I'll pull up a clear comparison table of the medications used in heart failure management to help you visualize the "Fantastic Four" pillars of treatment.

The management follows a "stepwise" approach, starting with the basics and adding more specialized therapies if symptoms persist.

The Stepwise Ladder:

1. First-line: Start an ACE inhibitor (or ARB) and a Beta-blocker. (Note: Start one at a time, usually the ACEi first unless the patient is already stable).
2. Second-line: If symptoms persist despite optimal doses of first-line therapy, add a Mineralocorticoid Receptor Antagonist (MRA) like Spironolactone.
3. The "Fantastic Four" Addition: SGLT2 inhibitors (Dapagliflozin or Empagliflozin) are now recommended for all patients with HFrEF regardless of diabetic status.
4. Specialist Options: If the Ejection Fraction remains $\le$ 35%, specialists may consider:
   • ARNI (Sacubitril Valsartan): Replacing the ACEi/ARB.
   • Ivabradine: If in sinus rhythm with HR $\ge$ 75 bpm.
   • Hydralazine + Nitrate: Especially in patients of Afro-Caribbean origin.
   • CRT/ICD: Cardiac resynchronization or defibrillators.

I've also found some high-yield lessons that cover these guidelines in more detail for your UKMLA prep.

Those lessons should give you a deep dive into the latest NICE guidelines. If you're feeling confident with the theory, I can also pull up some practice questions to see how this translates into clinical scenarios! Would you like to try a quick quiz on heart failure management?